🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As seen on Fox Business today, Chief Strategist at the Basenese Group, Lou Basenese, stated on eXoZymes' addressable market: "I mean, this sounds ridiculous, but it's in the trillions of market, I mean, trillions of dollars. And that's backed by McKinsey & Company - they did a study

$EXOZ... potential to be #synbio tech that can commercially scale unlike $DNA. Microcap worth 👀

We plan to host a webinar on Wednesday April 2, 2025 at 4:30 PM Eastern Time / 1:30PM Pacific to discuss its results for the fourth quarter and full year 2024. Michael Heltzen (Michael Heltzen), CEO of eXoZymes, will lead the call and will be joined by select members of the management

We plan to host a webinar on Wednesday April 2, 2025 at 4:30 PM Eastern Time / 1:30PM Pacific to discuss its results for the fourth quarter and full year 2024. Michael Heltzen (Michael Heltzen), CEO of eXoZymes, will lead the call and will be joined by select members of the management

From Chemical Engineering: “In our bio-transformations, getting rid of the cells avoids complexity and concerns about cell toxicity that are not usually present in traditional chemical catalysis. We are bringing on more of a traditional chemical mindset to an inherently biological

We're extremely happy to introduce our new CCO, Damien Perriman (Damien Perriman), who shares these words: “eXoZymes represents the new generation of SynBio design and scale-up, setting new standards for development speed and opening a range of commercially compelling product

Through a BioMADE project, member eXoZymes is taking a new approach to enzyme engineering in biomanufacturing by designing enzymes that can thrive outside living cells, eliminating complexity, improving reaction yields and innovating biofuel production: buff.ly/0BVpCsK

100 Industry Leaders Looking to Collaborate on What’s Next: AbbVie , Acies Bio , Aenea, Aikium, AKT, Allen Institute , Amazon , Ambrosia Space Manufacturing Corporation, Anodyne Chemistries, ANYg Labs, ArsenalBio , Arzeda , Astellas Venture Management, Asymchem ,

Dr. Tyler Korman (Tyler Paz Korman), co-founder and VP of Research at eXoZymes, on BioClick - supported by a NIH grant: “With our new BioClick tool set that incorporates artificial intelligence into our exozymes platform, coupled with our advanced enzyme engineering skills and

Our VP of Research Tyler Paz Korman was interviewed by Jane King on Bloomberg TV this Saturday: "What we're trying to do is really to redefine how people make chemicals. Chemicals that you use in your everyday life. These could be nutraceuticals or fuels - but in a sustainable

💥 enzymes x AI = exozymes 💫 We're excited to announce that we'll be sponsoring this year's SynBioBeta conference, May 5-8 in San José, CA! Get your tickets here: hubs.la/Q03hBn_f0 - and please let us know you're coming, so we can meet up! #synbiobeta2025 #enzymes

Cover story in GEN Biotechnology: Bringing clarity and precision to the cell-free space by introducing 'exozymes' as a scientific nomenclature. Dr. Tyler Korman (Tyler Paz Korman), co-founder and VP of Research at eXoZymes states, “By introducing exozymes as a common terminology, we

The team of in- and external authors are proud of getting the cover story in GEN Biotechnology - just released in their April issue. The aim of this peer-reviewed and Open Access article is to introduce 'exozymes' as a new scientific nomenclature to bring clarity in the cell-free

The 'exozyme era' of biotechnology is here, as member of the Strategic Advisory Board at Codexis and eXoZymes Board Member, Dr. Jim Lalonde, states: “As a concept, exozymes unlocks the increased leverage from the evolution of the biotechnology tool stack and its synergy with

eXoZymes "I think the biggest innovations of the 21st century will be at the intersection of biology and technology.” - Steve Jobs

AI transforming biotechnology: From form with AlphaFold to function with exozymes Co-founder and VP of Development at eXoZymes , Dr. Paul Opgenorth (Paul Opgenorth) - who's going to be at the BioMADE meeting this week - states: "The Large Language Models (LLMs) actually got